Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for AVM Biotechnology

    Client Virtual Booth

    AVM BIOTECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    AVM Biotechnology
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1749 Dexter Ave N, Seattle, WA 98109
    Telephone
    Telephone
    1(206)906-9922
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avmbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avm-biotechnology/
    Twitter
    Twitter
    https://twitter.com/avmbiotech?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    AVM Biotechnology Selected by the National Cancer Institute to Present
    AVM Biotechnology Selected by the National Cancer Institute to Present

    https://www.businesswire.com/news/home/20230911666899/en

    BUSINESSWIRE
    11 Sep 2023
    Share Share
    AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives
    AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives

    https://www.businesswire.com/news/home/20230809463056/en

    BUSINESSWIRE
    09 Aug 2023
    Share Share
    AVM Bio Announces Solid Tumor & Blood Cancer Patients Treated with AVM0703
    AVM Bio Announces Solid Tumor & Blood Cancer Patients Treated with AVM0703

    https://www.businesswire.com/news/home/20230731194052/en

    BUSINESSWIRE
    01 Aug 2023
    Share Share
    AVM Biotech Awarded $2M NCI SBIR PII Grant from NIH to Advance AVM0703
    AVM Biotech Awarded $2M NCI SBIR PII Grant from NIH to Advance AVM0703

    https://www.businesswire.com/news/home/20220614005414/en

    BUSINESSWIRE
    14 Jun 2022
    Share Share
    AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703
    AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703

    https://www.businesswire.com/news/home/20220601005424/en

    BUSINESSWIRE
    01 Jun 2022
    Share Share
    AVM Bio Founder and CSO to Present Company Information and Trial Progress
    AVM Bio Founder and CSO to Present Company Information and Trial Progress

    https://www.businesswire.com/news/home/20220419005486/en

    BUSINESSWIRE
    19 Apr 2022
    Share Share
    AVM Biotechnology Awarded $1.6M Phase II SBIR Grant to Study AVM0703’s Potential
    AVM Biotechnology Awarded $1.6M Phase II SBIR Grant to Study AVM0703’s Potential

    https://www.businesswire.com/news/home/20220405005529/en

    BUSINESSWIRE
    05 Apr 2022
    Share Share
    AVM Biotech Expands C-Suite in Anticipation of 2023 Commercialization Efforts
    AVM Biotech Expands C-Suite in Anticipation of 2023 Commercialization Efforts

    https://www.businesswire.com/news/home/20220309005116/en

    BUSINESSWIRE
    09 Mar 2022
    Share Share
    FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia
    FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia

    https://www.prnewswire.com/news-releases/fda-approves-accelerated-dosing-in-non-hodgkins-lymphomaleukemia-clinical-trial-301332693.html

    PRNEWSWIRE
    13 Jul 2021
    Share Share
    AVM Announces Full Enrollment of First Cohort of Relapsed/Refractory
    AVM Announces Full Enrollment of First Cohort of Relapsed/Refractory

    https://www.prnewswire.com/news-releases/avm-biotechnology-announces-full-enrollment-of-first-cohort-of-relapsedrefractory-non-hodgkins-lymphoma-patients-dosed-with-avm0703-at-major-cancer-centers-in-usa-301263637.html

    PRNEWSWIRE
    07 Apr 2021
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search